Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated

Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada Sara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 – Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis Talbot, PhD1,2 – Charles-Antoine Guay, MD MSc1,3 – Caroline Quach, MD MSc5,6 – Rodica Gilca, MD PhD1,2,3 – Jesse Papenburg, MD MSc8,9 1Social and preventive medicine department, Faculty of medicine, Laval University, Québec, Québec, Canada 2Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Québec, Québec, Canada 3Biological risk unit. Institut national de santé publique du Québec, Québec, Québec, Canada 4Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada 5Department of Microbiology, University of Montreal, Montréal, Canada 6Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montréal, Québec, Canada 7Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte- Anne-de-Bellevue, Québec, Canada 8Departement of pediatric, Montreal Children's Hospital of the McGill university Health Centre, Montréal, Québec, Canada 9Departement of epidemiology, biostatistics and occupational health, Université McGill, Montréal, Québec, Canada Corresponding author: Sara Carazo Department of social and preventive medicine, Laval University Institut national de santé publique du Québec 945 Wolfe Avenue, Quebec City, QC, Canada, G1V 5B3 +1 418 650 5115 sara.carazo@inspq.qc.ca; sara.carazo-perez.1@ulaval.ca